Shanghai Fudan Zhangjiang Bio Pharmaceutical Co (DE:FDY) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has recently commenced the crucial Phase III clinical trial of their novel FDA018 antibody drug conjugate, aimed at treating triple negative breast cancer, with the first patient successfully enrolled. The drug, which targets Trop-2 expressed tumor cells, has shown promising preliminary results in earlier trials with an overall response rate of 37.9% and disease control rate of 79.3% in TNBC patients. Investors are reminded of the inherent risks associated with the lengthy and uncertain process of pharmaceutical development.
For further insights into DE:FDY stock, check out TipRanks’ Stock Analysis page.
